预约演示
Xilio fires 21% of its workforce and reprioritises pipeline
2024-04-02
临床1期临床2期免疫疗法
Xilio expects to incur a one-time cost of approximately $1m for reducing its workforce by 15 employees. Image Credit: Andrii Yalanskyi / Shutterstock.
Xilio Therapeutics has implemented cost-cutting measures which include a 21% workforce reduction and the termination of investments for developing one of its assets, XTX202, as a monotherapy.
Xilio Therapeuticsncur one-time cost of approximately $1m for reducing its workforce by 15 employees. The company has reported $44.7m in cash reserves, which are expeXTX202o fund the company’s activities into Q2 2025. The Waltham, Massachusetts-based company’s market cap currently stands at $42.1m.
Xiliowing the recent round of layoffs, Xilio joins a list of pharmaceutical companies including Atreca, Candel Therapeutics, Kinnate Bio, and NexImmune that have fired workers to funnel more money into their clinical development pipelines in the last few months.
The company plans to not investigate XTXilio a tumour-activated beta-gamma biased interleukin (IAtrecaasCandel TherapeuticsinKinnate BioexplorNexImmuneships to develop the therapy as a combination treatment. The therapy was evaluated in an open label Phase I/II trial (NCT05052268) in 19 patients with metastatic renal cell carcinoma (RCC) and 20 patients with unresectable or metastatic melanoma. At nine weeks, the therapy was well tolerated and had a 76% and 50% disease control rate in 7 RCC and 9 melanoma patients, respectively.
Following the restructuring, Xilio plXTX202 foctumour resources on the two Phase I candidates — XTX101 and XTX301. Last week, the company licenced XTX301 to Gilead Sciences for upfront cash and equity payments totalling $43.5m. XTX301 is being evaluated in an open label Phase I trial (NCT05052268) in metastatic renal cell carcinoma (RCC) with pharmacokinetic unresectable or metastatic melanomaunresectable or metastatic melanomarial expected in Q4 this year.RCCmelanoma
Xilio and Gilead partner up for IL-12 therapeutic development
XTX101 is a fragmented crystallisable (Fc)-enhanced, anti-CTLA-4 antibody that depletes regulatory T cells when activated in the tumour microenvironment. The therapy is being evaluated as a monotherapy and in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in an open-label Phase I/II trial (NCT04896697). The trial is co-funded by Roche. For the Phase II portion of the study, the company plans to investigate the XTX101/Tecentriq combination in 40 patients with microsatellite stable colorectal cancer. The Phase II will be initiated in Q3 2024, with initial data from half of the participants expected in Q4 2024.
Another candidate in Xilio’s pipeline is a PD-1 and IL-2 bispecific antibody, XTX501, currently in preclinical development. Immuno-oncology is a growing area of focus, with over 400 therapies currently in development, according to GlobalData analysis.
GlobalData is the parent company of Pharmaceutical Technology.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。